

# بسم الله الرحمن الرحيم

 $\infty\infty\infty$ 

تم رفع هذه الرسالة بواسطة / مني مغربي أحمد

بقسم التوثيق الإلكتروني بمركز الشبكات وتكنولوجيا المعلومات دون أدنى مسئولية عن محتوى هذه الرسالة.

AIN SHAMS UNIVERSITY

1992

1992

ملاحظات: لا يوجد

### Comparison between Percutaneous Coronary Intervention versus Coronary Artery Bypass Graft with Mitral Valve Replacement in Patients with Single Vessel and Mitral Valve Disease

### **Thesis**

Submitted by **Taher Mohamed Eid AbdelMoneim**MSc Cardiothoracic Surgery

In partial fulfillment of MD Degree in Cardiothoracic Surgery

### **Supervisors**

Prof. Dr/ Walaa Ahmed Saber Professor of Cardiothoracic Surgery Faculty of Medicine - Ain Shams University

Prof. Dr/ Osama Abbas Abdelhamid Professor of Cardiothoracic Surgery Faculty of Medicine - Ain Shams University

Dr/ Moustafa Gamal ELBarbary
Lecturer of Cardiothoracic Surgery
Faculty of Medicine - Ain Shams University

Faculty of Medicine Ain Shams University 2022

## Acknowledgement

### "At first, I thank God; the most gracious and merciful"

I would like to express my deep gratitude to Professor **Dr. Walaa Ahmed Saber**, Professor of Cardiothoracic Surgery, Faculty of Medicine, Ain shams University, for his continuous guidance, his great support during the preparation of this work. His advices were the corner stone in building up of this study. There are no words that can sustain my gratitude to him.

I am also thankful to **Dr. Osama Abbas Abdelhamid**, Professor of cardiothoracic Surgery, Ain shams University, for his brotherly support and continued encouragement over the past months. His influence on this work has been truly inspirational.

Last but by no means least; I'd like to thank **Dr. Moustafa Gamal ElBarbary**, lecturer of cardiothoracic surgery, Faculty of Medicine, Ain shams University for his illuminating discussion and continuous support.

A final thank you goes out to my family, friends, and colleagues who have always supported me; sharing the good times and the most difficult of them as well.

#### **Abstract**

Introduction: Combined coronary artery mitral valve disease is a major cause of morbidity and mortality in the adult patient population. Traditional treatment involves combined mitral valve and CABG surgery using a median sternotomy. However, this combined surgical approach confers a higher risk when compared with isolated MV surgery, the risks of such a combined surgical procedure may outweigh the benefits. Thus, the concept of parsing the total risk of a single major procedure to the lesser individual and summed risks of 2 smaller procedures—percutaneous coronary intervention (PCI) plus the mitral valve operation—has been applied in clinical practice and reported by various groups.

**Methods:** The study was a prospective comparative review of 80 combined single coronary artery revascularization in non-LAD territory) and rheumatic MV disease, divided into two groups; Group I consisting of 40 patients who underwent staged PCI, and mitral valve replacement 3 months later, and Group II consisting of 40 patients who underwent combined CABG (using saphenous venous graft) and mitral valve replacement. The study centers were Cardiothoracic Surgery Department of Ain Shams University Hospitals, and National Heart Institute (NHI). PCI was done at Cardiology Department of Ain Shams University Hospitals, and National Heart Institute (NHI). The collected data was revised, coded, tabulated and introduced to a PC using statistical package for social Science (SPSS 15.0.1 for windows; SPSS Inc, Chicago, IL, 2001). The outcomes of interest are total cardiopulmonary bypass time, total cross-clamp time, the need for inotropic support, ECG changes in the form of ischemia or arrhythmias, bleeding, cerebrovascular accidents, renal failure, respiratory complications, duration of mechanical ventilation, duration of ICU stay, wound infection, duration of hospital stay, 30-day mortality, major cardiac events or CCU admission within first year, and the need for reoperation for myocardial infarction or ischemia within first year.

**Results:** The median aortic cross-clamp and cardiopulmonary bypass times were 44 and 62 minutes for Group I, vs 60.5 and 82 minutes for Group II, that difference between groups is statistically significant. 8 patients (20%) in Group I needed inotropic support vs 12 patients (30%) in Group II, which is not statistically significant. No patients in both groups did need any mechanical support in the form of intra-aortic balloon pump (IABP). None of the patients in both groups had

intraoperative ECG changes in the form of ischemia or arrhythmias. The median intensive care unit (ICU) length of stay (hours) and hospital length of stay (days) were 39 hours and 5.5 days for Group I, vs 56.5 hours and 8.5 days for Group II, that difference between groups is statistically significant. The median blood loss (ml) postoperatively was 925 (range 650-1200) in group I vs 1075 (range 900-1400) in group II, which is statistically significant. However, the rate of reexploration for bleeding did not differ significantly between both groups, with 1 case only (2.5%) in group I vs 2 cases (5%) in group II, and no postoperative delayed cardiac tamponade noted in any of the two groups. The post-operative complications for groups I and II included 0 (0%) vs 3 (7.5%) prolonged mechanical ventilation (>24 h), 0 (0%) vs 1 (2.5%) respiratory complications, 0 (0%) vs 2 (5%) wound infection, 0 (0%) vs 1 (2.5%) cerebrovascular accidents, 2 (5%) vs 1 (2.5%) acute kidney injury, respectively. There is no statistically significant difference between both groups regarding these previous post-operative complications. None of the patients in both groups died within the first 30 days after surgery. None of the patients in both groups had major cardiac events or CCU admission. Postoperative routine trans-thoracic echo (TTE) follow up upon discharge, after 3 months, 6 months, & 1 year were done for all patients in both groups. Regional wall motion abnormalities were noted in 15 patients (37.5%) of group I vs 17 patients (42.5%) of group II, who all undergone stress ECG, of whom 9 patients (22.5%) in group I vs 11 patients (27.5%) in group II showed positive results, and qualified for diagnostic coronary angiography, which confirmed the need for reoperation for myocardial ischemia/infarction within the first year of follow up post-operatively in 4 patients (10%) of group I vs 8 patients (20%) of group II. All these follow up outcomes showed no significant difference between both groups.

Conclusion: a staged approach of PCI followed by MVR is an alternative to the conventional combined CABG and MVR, can be performed safely in some patients with single coronary artery and MV disease, and is associated with good short and follow-up outcomes. Nevertheless, important questions remain, including the optimal timing of the individual procedures, and the optimal antiplatelet therapy after PCI. With ongoing advances in stent technology, procedural techniques, and anticoagulation strategies, as well as the accumulation of long-term outcomes data, hybrid approaches to concomitant coronary artery and mitral valve disease will likely become increasingly common. Tailoring the approach to individual patient pathology and comorbidities is feasible and offers potentially better treatment paradigms.

## **Table of Contents**

	Page No.
List of Tables	i
List of Figures	ii
List of Abbreviations	iv
Introduction	1
Aim of Work	5
Review	
1. Mitral Valve and Coronary Artery Anatomy	6
2. Mitral valve diseases	17
3. Indications for surgical treatment	23
4. Coronary artery disease	36
5. Indications for revascularization	44
6. Hybrid PCI and MVR	59
Patients and Methods	72
Results	77
Discussion	95
Limitations	117
Conclusion	118
Summary	119
References	126
Arabic Summary	

## **List of Tables**

Ta	bles Title Page No.
1	Common etiologies for primary and secondary mitral regurgitation
2	Recommendations for Intervention for Rheumatic mitral stenosis
3	Indications for intervention in severe primary mitral regurgitation
4	Indications for mitral valve intervention in chronic secondary mitral regurgitation
5	Indications for revascularization in patients with stable angina or silent ischemia
6	Recommendations for revascularization in non-ST-elevation acute coronary syndrome
7	Indication for revascularization in STEMI
8	Recommendation for the type of revascularization in patients with stable coronary artery disease with suitable coronary anatomy for both procedures and low predicted surgical mortality
9	Baseline characteristics of the study patients
10	Baseline characteristics of the study patients "continued" 81
11	Baseline characteristics of the study patients "continued" 82
12	Baseline characteristics of the study patients "continued" 84
13	Operative characteristics of the study patients
14	Postoperative outcomes of the study patients91
15	Follow up outcomes within first year of the study patients 94

# **List of Figures**

Fig	gure No. Title	Page No.
1	The mitral apparatus	6
2	Cross-sectional anatomy showing the mitral surrounding structures	
3	The mitral annulus	9
4	Mitral valve	10
5	Anterior and posterior coronary circulation	12
6	Right coronary artery branches	16
7	Intervention in mitral stenosis	24
8	Intervention in severe primary mitral regurgitation .	27
9	Intervention in severe secondary mitral regurgitation	ı29
10	Left atriotomy via Sondergaard's groove	30
11	Khonsari biatriotomy	31
12	Prosthesis Orientation	32
13	Annular Reconstruction	34
14	Artery structure	37
15	Pathology of coronary artery atherosclerosis	41
16	Aspects favoring percutaneous coronary interve coronary artery bypass grafting	
17	Balloon catheter in PCI	49
18	IMA harvest	52
19	GSV harvest	53

20	Prior to initiation of cardiopulmonary bypass, all conduits should be inspected for usability	. 54
21	End to side anastomosis	. 55
22	Right mini-thoracotomy: mitral valve exposure. A static atrial retractor aids in valve exposure	. 71
23	Sex distribution among study groups	. 79
24	Medical history among study groups	. 80
25	Coronary lesions among study groups	. 85
26	Mitral valve lesions among study groups	. 86
27	Need for inotropic support intraoperatively	. 88
28	Operative characteristics among study groups	. 89
29	Post-operative outcomes among study groups	. 92

## **List of Abbreviations**

**ACC** American College of Cardiology

**ACS** Acute coronary syndrome

**ADP** Adenosine diphosphate

**AF** Atrial fibrillation

AHA American Heart AssociationAMI Acute myocardial infarction

**AMI** Acute mesenteric ischemia

**AV** Atrioventricular

**BMI** Body Mass Index

**CABG** Coronary artery bypass graft

**CAD** Coronary artery disease

**CCU** Cardiac Care Unit

**COPD** Chronic obstructive pulmonary disease

**CPB** Cardiopulmonary bypass

**DES** Drug-eluting stents

**EACTS** European Association for Cardio-Thoracic

Surgery

**ECG** Electrocardiogram

**EF** Ejection Fraction

**ESC** European Society of Cardiology

**GP** Glycoprotein

**GSV** Great saphenous vein

**IABP** Intra-aortic balloon pump

**ICU** Intensive Care Unit

**IMA** Internal mammary artery

**INR** International normalized ratio

**IQR** Interquartile range

**LA** Left atrium

**LAD** Left anterior descending artery

**LM** Left main

**LV** Left ventricle

**MIMVS** Minimally invasive mitral valve surgery

MIVS Minimally invasive valve surgery

MR Mitral regurge

MS Mitral stenosis

**MV** Mitral valve

**MVD** Mitral valve disease

N Number

NSTEMI Non ST segment Elevation Myocardial

Infarction

**PAP** Pulmonary artery pressure

**PARs** Protease-activated receptors

**PCI** Percutaneous coronary intervention

**PMBC** Percutaneous mitral balloon commissurotomy

**RBCs** Red blood cells

**SB** Side branch

**SD** Standard deviation

**STEMI** ST segment Elevation Myocardial Infarction

STS Society of Thoracic Surgeons

**SVT** Supraventricular tachycardia

SYNTAX Synergy Between Percutaneous Coronary

Intervention With TAXUS and Cardiac

Surgery trial

TTE Trans-thoracic echo

**TXA2** Thromboxane A2

**VSMCs** Vascular smooth muscle cells

VT Ventricular tachycardia

**vWF** von Willebrand factor

## **INTRODUCTION**

The concept of the hybrid operation emerged in the mid-1990s as a strategy for coronary revascularization in the setting of acute myocardial infarction (AMI) [1]. In the most common scenario, a patient who presented with an AMI was emergently taken for angioplasty and found to have multivessel disease. The culprit lesion was treated percutaneously, and the remaining coronary disease was treated with a subsequent CABG. Thereafter, staged PCI and CABG, frequently with off-pump or minimally invasive CABG, was developed as a treatment option for elective coronary revascularization [2-5]. Expanding on this concept, it was realized that patients with valvular disease who presented with an AMI could be managed similarly. First described in 2005 by Byrne et al., the hybrid approach was defined as a staged procedure with initial PCI in the cardiac catheterization laboratory followed by open valve surgery during the same admission. With further experience it became apparent this hybrid approach could be extended to elective procedures. This strategy produced excellent outcomes and paved the way for single-stage procedures [6].

As the complexity of patients referred to cardiac surgery increases, integrated hybrid therapy is becoming an increasingly popular treatment option for patients with

#### Introduction

cardiovascular disease. This stems from the fact that this therapeutic strategy entails less-extensive surgical trauma and has the capacity to curtail the magnitude of the surgery involved. By doing so, it has the potential to decrease operative risk while not compromising the outcomes. Furthermore, hybrid strategy combines the tools available to the surgeon with those available to the cardiologist to treat any set of lesions [7].

Interest in hybrid procedures, defined for the purpose of this thesis as Mitral valve surgery and percutaneous coronary intervention (PCI), has intensified with improved coronary stent technology, increased collaboration between cardiac surgeons and interventional cardiologists, and the introduction of hybrid operating suites. The complementary goals of minimizing the morbidity of surgical procedures and optimizing resource utilization have driven development of new solutions for concurrent valvular and coronary heart disease [8].

Combined coronary artery mitral valve disease is a major cause of morbidity and mortality in the adult patient population. Traditional treatment involves combined mitral valve and CABG surgery using a median sternotomy. However, this combined surgical approach confers a higher risk when compared with isolated MV surgery [9,10]. Typically, patients are sicker, operative times are longer, and

### Introduction

morbidity and mortality are increased. Moreover, this combined surgical approach may prove to have a prohibitively high risk in some patients. For instance, in patients with mitral valve disease and either acute coronary syndrome, poor conduit quality, or poor target-vessel quality, as well as low ejection fraction, and in patients undergoing reoperative cardiac surgery, the risks of such a combined surgical procedure may outweigh the benefits [11,12]. Thus, the concept of parsing the total risk of a single major procedure to the lesser individual and summed risks of 2 smaller procedures—percutaneous coronary intervention (PCI) plus the mitral valve operation—has been applied in clinical practice and reported by various groups [13,14].

A hybrid approach that combines PCI with Mitral valve surgery is worthy of consideration and has demonstrated excellent early and mid-term outcomes [15,16]. It has been associated with a lower morbidity and shorter hospital length of stay, when compared with conventional CABG and Mitral valve surgery [17,18]. Patients with combined Mitral valve and CAD with acute coronary syndrome are particularly suitable for this approach, where PCI is performed to the "culprit lesion" followed by valve surgery [19].

Hybrid procedures (PCI and Mitral valve surgery) can be performed as a "two-stage" procedure in two different